Clinical Trial Update: A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating RO5083945 with FOLFIRI versus FOLFIRI plus cetuximab or FOLFIRI alone as second-line therapy in metastatic colorectal cancer (completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• RO5083945

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED